Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Net Income towards Common Stockholders: 2020-2024

Historic Net Income towards Common Stockholders for Prime Medicine (PRME) over the last 5 years, with Dec 2024 value amounting to -$195.9 million.

  • Prime Medicine's Net Income towards Common Stockholders rose 3.69% to -$50.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.3 million, marking a year-over-year increase of 9.99%. This contributed to the annual value of -$195.9 million for FY2024, which is 1.14% up from last year.
  • Latest data reveals that Prime Medicine reported Net Income towards Common Stockholders of -$195.9 million as of FY2024, which was up 1.14% from -$198.1 million recorded in FY2023.
  • Prime Medicine's 5-year Net Income towards Common Stockholders high stood at -$5.1 million for FY2020, and its period low was -$198.1 million during FY2023.
  • Its 3-year average for Net Income towards Common Stockholders is -$178.7 million, with a median of -$195.9 million in 2024.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first slumped by 3,542.31% in 2021, then increased by 22.87% in 2022.
  • Yearly analysis of 5 years shows Prime Medicine's Net Income towards Common Stockholders stood at -$5.1 million in 2020, then plummeted by 3,542.31% to -$184.1 million in 2021, then rose by 22.87% to -$142.0 million in 2022, then tumbled by 39.52% to -$198.1 million in 2023, then increased by 1.14% to -$195.9 million in 2024.